Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002887 | 0.92 | ELANE (0.35) | ELANEHPGDLCKNPC1RAB9A | |
| SCHEMBL10003404 | 0.89 | HTT (0.40) | HPGDKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL10004018 | 0.87 | ALDH1A1 (0.41) | HPGDTRPA1NPC1RAB9AMAPT | |
| SCHEMBL10003167 | 0.86 | F10 (0.40) | HPGDRAB9AMAPT | |
| SCHEMBL10004022 | 0.85 | MAP3K5 (0.36) | INSRITKTRPA1 | |
| SCHEMBL10003568 | 0.85 | NPC1 (0.44) | HPGDNPC1RAB9AMAPT | |
| SCHEMBL10003577 | 0.85 | HPGD (0.36) | GRM5HPGDCASP3SENP8SENP7 | |
| SCHEMBL10003422 | 0.85 | PTK2 (0.41) | HPGDINSRITKLCKKCNK3 | |
| SCHEMBL10003069 | 0.85 | SMN1; SMN2 (0.41) | NPC1RAB9ATEKMAPT | |
| SCHEMBL10003789 | 0.85 | ALDH1A1 (0.42) | HPGDTRPA1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471789-B9 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-2471789-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | ELANE 4378/4885GRM5 1656/4885HPGD 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.